ReviewJournal of diabetes and metabolic disorders2026
Enteroendocrine hormones and gut microbiota in obesity: a systematic review from mechanistic insight to precision metabolic care.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This systematic review aims to synthesize current evidence on enteroendocrine cell alterations in obesity, elucidate the mechanisms by which gut microbial taxa and metabolites regulate gut hormone release, and assess therapeutic innovations targeting the microbiota-enteroendocrine axis for precision metabolic care. Methods: A systematic search of PubMed, Web of Science, Scopus, and Embase was conducted from January 2015 to July 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Studies examining enteroendocrine cell function, gut microbiota composition, and their metabolic interactions in human obesity, animal models, and cellular systems were included. Data were extracted on gut hormone levels, microbial community structure, short-chain fatty acid production, and therapeutic interventions. Quality assessment was performed using the Cochrane Risk of Bias tool for randomized controlled trials and Newcastle-Ottawa Scale for observational studies. Results: Microbial dysbiosis characterized by depletion of short-chain fatty acid-producing bacteria is associated with impaired gut hormone release and altered free fatty acid receptor signaling. Therapeutic strategies including glucagon-like peptide-1 receptor agonists are associated with substantial weight loss, whereas probiotics, prebiotics, and fecal microbiota transplantation show variable and generally modest metabolic effects in human studies. Conclusion: The microbiota-enteroendocrine axis represents a promising therapeutic target for obesity management, supported by mechanistic and associative evidence.Multi-modal precision approaches integrating hormonal pharmacotherapy with microbiota modulation may enable more durable metabolic benefits and personalized obesity treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.